1-4 of 4
Katja Brocke-Heidrich
Close
Sort by
Journal Articles

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

Andreas Guenther, Renate Burger, Wolfram Klapper, Markus Tiemann, Frank Bakker, Katja Brocke-Heidrich, Friedemann Horn, Martin Gramatzki
Journal: Blood
Blood (2009) 114 (22): 1843.
https://doi.org/10.1182/blood.V114.22.1843.1843
Published: 2009
Journal Articles

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Brief Report
Dennis Löffler, Katja Brocke-Heidrich, Gabriele Pfeifer, Claudia Stocsits, Jörg Hackermüller, Antje K. Kretzschmar, Renate Burger, Martin Gramatzki, Conny Blumert, Kay Bauer, Helena Cvijic, A. Kerstin Ullmann, Peter F. Stadler, Friedemann Horn
Journal: Blood
Blood (2007) 110 (4): 1330–1333.
https://doi.org/10.1182/blood-2007-03-081133
Published: 2007
Includes: Supplemental data
Journal Articles

Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.

Andreas Günther, MD, Markus Tiemann, M.D., Frank Bakker, Ph.D., Wolfgang Baum, Ph.D., Katja Brocke-Heidrich, Ph.D., Friedemann Horn, Ph.D., Renate Burger, Ph.D., Martin Gramatzki, M.D.
Journal: Blood
Blood (2006) 108 (11): 3428.
https://doi.org/10.1182/blood.V108.11.3428.3428
Published: 2006
Journal Articles

Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activation

Katja Brocke-Heidrich, Antje K. Kretzschmar, Gabriele Pfeifer, Christian Henze, Dennis Löffler, Dirk Koczan, Hans-Jürgen Thiesen, Renate Burger, Martin Gramatzki, Friedemann Horn
Journal: Blood
Blood (2004) 103 (1): 242–251.
https://doi.org/10.1182/blood-2003-04-1048
Published: 2004
Includes: Supplemental data